Lela Buckingham to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications Lela Buckingham has written about Cyclin-Dependent Kinase Inhibitor p16.
Connection Strength
0.689
-
CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
Score: 0.412
-
Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis. Int J Exp Pathol. 2021 12; 102(6):232-241.
Score: 0.191
-
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
Score: 0.086